Nicotine patch labeling on preventing relapse suggested by McNeil.
This article was originally published in The Tan Sheet
Executive Summary
NICOTINE PATCH PREVENTING RELAPSE LABELING SUGGESTED BY McNEIL as a proposed revision of current labeling for OTC smoking cessation products. McNeil Consumer Products bases its comments on the clinical trial it submitted as part of its 1995 NDA for the Rx-to-OTC switch of the Nicotrol 15 mg nicotine patch. The comments are intended as a preview to FDA's June 9 Drug Abuse Advisory Committee meeting on revising nicotine patch labeling (mostly Rx products).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning